Women in Engineering Grant 2022 180 views

View a PDF of this article

Article written and provided by get it made

To celebrate International Women in Engineering Day on 23rd June, Get It Made are excited to announce a £10k grant for female-founded or led engineering organisations. According to the latest figures available from the Women’s Engineering Society and ONS, as of 2021 just 12% of the engineering industry, and 25% of the manufacturing industry are female. In a bid to combat this gender imbalance within the industry, manufacturing specialists, Get It Made, are encouraging female-led organisations within engineering to apply for this grant that can take their work to the next level. In positive news, there has been an increase of 7.6% in female representation over the past decade, and we hope this grant can help to continue this trend. As well as the £10k grant, Get It Made will also be offering its expertise to help support small female-led engineering businesses through their manufacturing and supply chain challenges. Applications for this grant close at midnight on July 31st 2022, and can be submitted through the website here: https://get-it-made.co.uk/grants/women-in-engineering

John Jex, Senior Partner at Chemical Search International attends CHEMUK2022 218 views

John Jex, Senior Partner at Chemical Search International, is delighted to be attending CHEMUK2022 on Wednesday 11 May. If you are attending and would like to meet up, please contact John at jwj@chemicalsearch.co.uk

https://www.chemicalukexpo.com/

NobleNet Business Subscription | Free one month trial 174 views

View a PDF of this article

NobleNet Business Subscription | Free one month trial Launched in 2021 NobleNet is a premier network for professionals working globally across key STEM-based industries. To fuel our growth we are delighted to offer you the above promotion to advertise Jobs, Events or your Business. Just use the promotional code at the Business subscription checkout.

✓ Advertise on Jobs, Events, Marketplace

✓ Unlimited ads while your subscription is live

✓ Access all CV’s / Resume’s on member records

✓ Search & Alert anyone of interest with just one click 

All this for just £95/ month. Subscription can be cancelled any time. To access the trial you need to enter your card details on the payment page. The first month is free and you will not be charged until 1 month from the start date, unless cancelled before. We have zero access to card details. Promotional Code: FEB2201 (for further details see the PDF)

Chemical Search International attends WPC Houston 2022. To meet up please contact us. 222 views

Chemical Search International (CSI) is delighted to be attending this year’s World Petrochemical Conference in Houston, March 22 -25, 2022. The event offers an unparalleled network of leading industry executives featuring major chemical companies and leading organizations, all present to  discuss the critical issues that impact the chemical market. If you are attending and would like to catch up to discuss executive search requirements or your own career please contact Stephen Mothersole.

Hope to see you there. WPC – World Petrochemical Conference | IHS Markit

Chemical Search International – New Focus, New Clarity 271 views

We are delighted to announce a new focus and clarity for Chemical Search International in our quest to become the world’s finest executive search firm for the chemicals sector.

Born in 2000 we have weathered many changes in the chemicals cycle, world economy and recruitment patterns. Our simple model set out 21 years ago of sector focus, quality delivery, genuine integrity and a nimble approach has won us a wonderful client base (we thank you) and has never been more relevant for the world in 2021. As a company we have grown from just 1 employee to a great team of over 20 based in Europe, USA and Asia and leveraged by over 70 senior industry advisors.

What’s changed? A sharpened focus on our core strengths of executive search in all things ‘chemical’ which now embraces those wonderful elements of the periodic table, Lithium and Hydrogen in developing bench strength in clean energy. We are also polishing up expertise from our earliest roles in 2000 in rare earth metals, now back in the spotlight as never before, and expanding our reach into biocatalysis, green, renewable and the circular economy. Refresh yourself at www.chemicalsearch.co.uk

Meanwhile we spun off our networking activities into a dedicated new venture NobleNet. This aims to unite people right across the dynamic and rapidly converging STEM sector and offers simplicity, relevancy and value. Its not yet the finished article (but then even LinkedIn wasn’t built in a day!) but we are already planning new features and benefits. The site is live and we are currently offering free advertising subscriptions, so please take advantage at www.staging.noblenet.co

We hear of exciting new innovations every day in the rapidly changing worlds of chemicals, energy, materials and biosciences and we look forward to delighting our clients for the next 20 years.

So please follow us, like us, or whatever else we do in 2021 to support each other and if we can help in your recruitment plans or personal career development please get in touch.

Top 3 things to understand before appointing M&A advisors 257 views

Written by CCD Partners

Most of CCD Partners’ people have led (or are leading) chemicals or life sciences companies and in doing so have at one time or another appointed advisors to help them with M&A or other major corporate development events.

Now that we also work on the other side of the fence, we thought it would be an interesting exercise to collate our thoughts on where we went wrong and what our advice is to anyone thinking about appointing M&A advisors today.

Three common themes emerged…broadly summarised as “How”, “Who”, and “Why”.


1. How – understand how an advisor plans to add value

Every M&A advisor worth their salt will tell you that they add value. For sell-side deals this typically takes the form of promising to increase the sale value of your business. For buy-side deals it is harder to measure, but typically relates to promises to realise synergistic or strategic value for the buyer.

The trap many of us fall into is focusing on the number that is quoted as the “estimated achievable value”. Ultimately this is at best an honest guess based on imperfect information, at worst it is a cynical attempt to promise a high value and win a client – the only value that matters is the one that is achieved on completion.

Far more important than the estimate is how the advisor proposes to maximise the value achieved for you. Anyone can put a high number on a proposal, but not everyone can explain an effective strategy, show how they can execute that strategy, and demonstrate a track record of success doing the same. A number on its own is meaningless.

Useful questions to understand “how” include:


  • What types of companies present potential strategic value in a business combination?
  • How would you pitch my business to each of these groups to persuade them to engage?
  • What are the core pillars/objectives of your strategy to secure strategic premium?
  • What are the core workstreams you will lead to achieve these objectives?
  • What does this look like in terms of the process you would expect for my business?
  • Why are you best suited to run this strategy for us?
  • Why do you think you’re better placed than other advisors?
  • How much do you charge and what is your average fee to added value ratio?


The overall aim here is to understand how likely the advisor is to maximise the value that might be achieved.

2. Who – understand who on the advisory team will actually do most of the work

The traditional M&A advisory model is to put together an advisory team consisting of a partner, a couple of senior managers, and a number of junior analysts, all spending a reasonably large proportion of their time on the project. However, below a certain deal-size this model begins to break down. The fees are not high enough to support the deep teams that are required for larger projects and partners are forced to delegate a higher proportion of the work to the more junior members of the team.

The trap here is meeting the partner and senior managers during the pitching phase, whereas once the project begins >80% of the work is done by the more junior or mid-range analysts. Partners and senior managers turn up to key meetings, but they are not embedded in the detail as they would be on larger deals. One effectively ends up with some bright, but relatively inexperienced, analysts running the project with some senior support at key moments.

Unfortunately for this approach, smaller businesses tend to be more difficult to analyse, and more difficult to manage because they often haven’t yet been professionalised or had to cope with the demands of institutional investors. So, if anything, more senior input is required, not less. It simply isn’t appropriate to apply an advisory model designed for $1bn businesses to a $100m, $50m, or $10m business.

Useful questions to understand “who” include:


  • What deal size do you typically work on?
  • How many deals does the partner work on at any one time?
  • What is the role of everyone on the deal team?
  • Who will lead the deal and who will coordinate financial analysis?
  • Can we meet all the key members of the deal team?
  • What kind of access will we get to the partner day-to-day?
  • Who provides additional senior support as backup to the lead partner?

The overall aim here is to understand who in the team will be doing the key work so that you can assess their competence and whether you can work with them day-to-day, potentially for a year or more.




3. Why – understand the motivations and incentives of the individual advisors

You’ve established the advisors have a great strategy and track record, you rate and can work with the individuals that will be doing the day-to-day work, but how do you know the advisory team is truly and completely on your side and giving it their all?

Again, this is a real issue many of our team have seen in practice, there are stories galore of less-than-honourable or conflicted advice and examples of large advisory firms taking on small clients who are later neglected in favour of larger more prestigious projects. I will not share specific examples in print but please feel free to call and ask…

To mitigate the risk of receiving bad advice or a sub-standard service, one should 1) try to ensure one’s advisors are properly incentivised to achieve your objectives, 2) that the potential rewards are significant to them (i.e. your project is in their size “sweet spot” they are not likely to suddenly pick up a project that is 4 times as big), and 3) that they focus on projects like yours (i.e. your project isn’t an occasional “side project” for them and their main or preferred source of income is something else like working for repeat private equity or audit clients).

Useful questions to understand “why” include:


  • How are your firm’s fees structured so if we win, your firm wins?
  • How are you personally remunerated? What targets do you have to meet in order to achieve a bonus and/or promotion?
  • How are you personally rewarded if our objectives are, or are not, achieved?
  • What are your and your firm’s typical fee size/project size?
  • What are the smallest and largest deals you’ve worked on personally and your firm has worked on more generally?
  • Do you typically work for clients with our profile? Does your firm?
  • Do you have any repeat clients that are important to you? Does your firm?


The overall aim here is to understand what motivates the individuals working for you. You should gather enough information so you can assess whether or not they are properly incentivised to achieve the best possible result for you.


By bringing together the three strands of “How”, “Who”, and “Why”, you can move past a would-be advisor’s ‘elevator pitch’ to gain a strong understanding of the team that will be supporting your initiative, their strategy for success, and their alignment with your motivations in delivering an exceptional outcome.

CCD Partners advises Charnwood Molecular on investment by Synova Capital 250 views

Written by Matt Dixon for CCD Partners

CCD Partners is pleased to announce the investment by Synova Capital in Charnwood Molecular, an award-winning CRO serving the pharmaceutical, biotechnology, and chemical industries.

The deal provides Charnwood with capital to support and accelerate the continued growth and development of the business.


About Charnwood Molecular

Charnwood is one of the UK’s leading providers of outsourced drug discovery services, supporting an international client base of pharmaceutical and biotech companies in developing novel drugs.

Originating from Loughborough University, the company has expanded into premises within BioCity, Nottingham, and delivers services across medicinal chemistry, process research & chemical development and custom synthesis.

About Synova Capital

Synovainvests in UK growth opportunities with a particular focus on companies valued between £20m and £100m. Key verticals include Healthcare & Education, Technology, Business Services and Financial Services.

“Developing the next generation of pharmaceuticals”

Announcing the investment, Charnwood’s CEO and founder, Steve Allin, stated: “We are extremely excited about what we can achieve in partnership with Synova. Synova supported our business over an extended period prior to their investment, helping us to develop a strategic plan that we are all committed to delivering. They were able to leverage their sector expertise and introduced the business to a number of leading industry figures who will help us to grow going forwards. With Synova’s support we now have the resources to accelerate growth of our core service offering and to develop further specialist services to support our clients to develop innovative new treatments.”

Partner and Head of Healthcare for Synova, Tim Ashlin, added: “Having tracked Charnwood’s progress for a number of years, we are delighted to announce this investment to fuel Charnwood’s ambitious growth plans. It’s exciting to be supporting a business that is focused on developing the next generation of cutting-edge pharmaceuticals, and to support the continued growth of the UK life sciences industry.”

CCD Partners’ role

The CCD team was engaged to plan and execute a transition of ownership that would secure the future success of Charnwood.

We worked closely with the founders to assess all strategic options, build targeted business plans, and select and structure the transaction.


Steve Allin, founder and CEO of Charnwood, commented: 

“CCD Partners provided Charnwood with excellent strategic advice and planning which ultimately led to a successful major investment into the business by Synova Capital. During a lengthy and highly technical process, CCD partners worked hard to identify and capture potential strategic value for the founders, and were able to protect that value during negotiations.

Importantly, the efforts put in by CCD Partners enabled us to continue to focus our own efforts on the day to day growth of our business during the process. It is our belief that we would not have achieved the final value withoutthe close support of CCDPartners.”
 

Phil Page, founder of Charnwood, commented: 

“We are delighted with the deal and with the CCD Partners team. We’ve achieved our original goal of planning a sensible transition for the founders, and, as part of CCD’s process, we have also developed a future investment and growth strategy well beyond our original expectations.

Charnwood now has highly invested and experienced figures at the helm and is set for a very bright future. The CCD team was instrumental in realising this potential for us and, for anyone considering a similar transition process, I cannot recommend them enough.”

Can you reliably “beat the market” when selling your chemicals or life sciences business? 134 views

(Yes, and here’s how….)

Written by CCD Partners

There is a reasonably common view amongst business owners that one should wait to be approached by a ‘really keen strategic buyer’ before engaging in sale discussions. The reasoning being that if the buyer approaches first this gives the seller the upper hand in negotiations and means there is a good chance of a buyer being interested.

This, on its own, is wrong and, rather counter-intuitively, gives away the upper hand and can lead to sellers trapped into below-market deals or no deal at all after months of hard work.

I previously wrote an article on what to do if you are approached by a ‘really keen strategic buyer’which looked into how sellers can give themselves the best chance in such a scenario. The thrust of this article is that sellers in this situation are starting on the back foot and must work hard to catch up and be lucky enough to be dealing with a counterparty that is both highly motivated and unusually honourable.

Rather than relying on such a buyer-led approach, I typically recommend a seller-led approach. Using the methods I outline below I have enjoyed 100% success in securing above-market sales over my last 4 years and 7 deals (ever since I started employing these methods in their current form).


How to reliably beat the market when selling a lower-mid market (i.e. valued between $10m to $100m) privately-owned chemicals or life sciences business.

At the most basic level, securing a high price for a business requires a) the buyer to believe it is worth a high price, b) the buyer to believe they have to pay a high price, and c) nothing to go wrong before completion.

So, to achieve each of these, the core objectives of any seller-led sale process should be:

Objectives

  • Maximise the perceived value of the business to buyers “Value Perception”
  • Maximise the negotiation power of the sellers “Negotiation Power”
  • Maximise the certainty that the deal will complete “Deal Certainty”

Every business is unique, and every sale process should be tailored accordingly, but it is possible to talk in general about the following core workflows:

Workflows

  1. Narrative Development
  2. Preparation and Presentation
  3. Process Design

Taking each in turn…

1. Narrative Development

As I explore in my article “The most important thing to do when selling a chemicals or life sciences company” , developing a single compelling transaction narrative is critical to value. Such a narrative needs to inspire excitement in buyers, pull together all the strands of the deal in an understandable way, and build the platform for negotiations.

The narrative is the backbone of any process and is critical to get right.

Specific examples of what the narrative must do include:

  • Value Perception – ensure buyers are convinced of the strategic potential to them
  • Negotiation Power – ensure buyers believe there are credible alternatives to their offer
  • Deal Certainty – ensure the business appeals to a good number of buyers

2. Preparation and Presentation

Selling (and buying) a business is highly complex with hundreds of variables that each impact the final value. How the data is analysed, how it is presented, and how it is incorporated into any deal are all decisions that need to be made at various stages throughout the process. Furthermore, the sale of a company is not just about the business being sold – it is also about how that business might fit and interact with potential buyers’ businesses, which can often be in less-familiar markets.

As I discuss in my articles “When is analytical commercial due diligence not enough” and “How are privately-owned chemicals and life sciences companies valued” , a thorough grasp of accounting, transaction structuring, company valuation, and a techno-commercial understanding of multiple interacting dynamic markets is all simultaneously required to optimally prepare and present a chemical company for sale.

Specific examples of preparation and presentation required include:

  • Value Perception – ensure that sellers identify and present the full potential value of their business to all buyers (even those in less-familiar markets)
  • Negotiation Power – ensure all the key details are known and understood when headline deal terms are agreed
  • Deal Certainty – minimise the chance nasty surprises (internal or external) are revealed during due diligence

3. Process Design

A key aspect of a seller-led process is that the sellers can design and time the process to suit them. In a seller-led process it is much easier to design a timetable of work that focuses negotiation power during the short windows during which the key terms of a potential deal are agreed, that leaves sufficient time to prepare and execute with potential buyers, and that coincides with favourable seasonal conditions associated with the seller’s business (e.g. accounts preparation, typically strong sales months, and others).

Additionally, as I discuss further in my article “Selling your chemicals or life sciences business: why a slow process can erode value, and how to avoid it” , a slow process can kill a deal and so must be avoided through good process design.

Specific examples of what the process must do include:

  • Value Perception – ensure the business is perceived as a ‘prize asset’ being sold through a highly professional tailored process
  • Negotiation Power – ensure the factors that maximise negotiation power are focused to apply during the periods in which deal terms are agreed
  • Deal Certainty – minimise the time the business is “on the market” (when it is vulnerable to otherwise uncontrollable external factors)


In conclusion

It is possible to sell a lower-mid market privately-owned chemicals or life sciences business at above-market values.

However, to do it reliably, requires all of the following:

  1. a full range of transaction skills and techno-commercial insight into adjacent niche markets,
  2. a specialist and wide-reaching network of potential buyers and investors, but most of all
  3. a pro-active seller-led approach and highly dedicated work ethic that is focused on delivering the three core objectives of Value Perception, Negotiation Power, and Deal Certainty.

I have not seen it work any other way. Yes, it can help if a seller is approached before or during such a process and there are success stories from buyer-led deals, but these are comparatively rare and the failures (that are typically not made public) are far more numerous.

If you are interested in reading more on this topic I recommend “How much should you pay an M&A advisor to sell your chemicals or life sciences business?” , which sets out more on the different styles of approach to company sales and the associated success rates.

Innovation accelerators in the chemicals industry 115 views

Written by Sarah Harding for CCD Partners

Business leaders in the chemicals space should be aware of the support offered by innovation accelerators in their fields, as demand for ever faster routes to market places them under new pressures.

Modern R&D models are being built on the integration of physical, chemical and computer sciences, and a commercial model that is increasingly played out within a framework of innovation across public, private and not-for-profit entities. Under this model, successful innovators are increasingly taking advantage of ‘innovation accelerators’ to develop, test and grow new ideas.

High-profile examples include the UK’s NHS Innovation Accelerator, a revolutionary programme that gives innovators the skills and guidance to support innovation in the healthcare sector, and Horizon 2020 (H2020), the main European funding programme for research and innovation. H2020 has a budget of €79 billion and is intended to remove barriers to innovation, and make it easier for the public and private sectors to work together within fields as diverse as nanotechnology, food security, green energy and healthcare. On a smaller scale, several large corporations (e.g. BASF, DuPont) have recently begun to nurture start-ups by hosting efforts top bring in outsider technology and foster an entrepreneurial spirit. 
 
Of course, the process for being accepted by an accelerator is competitive – typically, less than 5% of applicants are accepted, but even an unsuccessful application procedure can be a learning experience and may provide realistic insights into the likelihood of success, or the need for a different approach. The lucky 5% should benefit from intensive expert focus on development and progress, including networking with other industry support providers and further investors. Just remember that funding is generally offered in exchange for equity – and what might seem like a small slice of cake now, might be quite large if your project is successful!
 
Business leaders in the chemicals space should be aware of the support offered by innovation accelerators in their fields, as demand for ever faster routes to market in an ever more competitive world places them under new pressures. The right accelerators can provide invaluable support for organizations in the early and fragile stages of product development, helping them avoid common mistakes, saving time and money, and increasing success rates. However, make sure you understand the value and pay-back, and how the programme will benefit your organization. 
 
Sarah J Harding, PhD is a communications specialist with 20+ years of experience in the pharmaceutical and speciality chemicals sectors. 

Is pharma’s innovation model the right approach for the chemical industry? 156 views

Written by Anil Vaidya for CCD Partners

Fifteen to twenty years ago pharma was struggling with a number of approaching patent expiries for their blockbuster drugs and sales were being threatened by the fast follower generics industry. Lack of innovation and failure to develop new drugs to replace those going off patent was seriously being questioned in boardrooms. 

Twenty years on and the pharma industry has completely changed its operating model – because they had to adapt. Drug discovery and drug development pipelines, the mainstay of traditional pharma, has now for many companies been partially or wholly subcontracted to contract research organisations providing services such as medicinal chemistry. Partnering with more nimble start ups with in-licensing deals helps feed pharma pipelines. This is an acknowledgement of the need to adopt new scientific findings and manufacturing processes.
 
The benefits of outsourcing include accessing skills, labour, and equipment that pharma might not have, at a price that is competitive to in-house development. Partnering offers an opportunity to de-risk new drug development, and adopting new science and processing techniques means a chance to develop innovative medicinal solutions. 
 
In short, pharma companies have become orchestrators of a complex set of moving parts to develop and bring new products to market.
 
Is there a lesson that can be learnt by the chemical industry here?
 
The chemical industry faces threats from multiple flanks and is heading into a perfect storm of demands, including pressures to transition to a circular economy, to reduce the use of plastics, to protect the environment, and a widespread emotional dislike for smoke stacked industries. 
 
It may now be time for the chemical industry to take a leaf out of pharma’s book and become comfortable with innovation, developing partnerships and not perceiving them as threats. 
 
Bringing a new product to market is always challenging and perhaps ‘big chemical’ could look at developing partnerships and licensing agreement with the start-ups in the chemical sector. This would benefit not only the chemical industry in identifying new assets and working practices, but would also help the chemical start-up industry which is woefully behind the pharma/biotech start up sector.
 
There could also be benefits in a change in mind-set amongchemical industry executives when talking about innovation. Many cite the regulatory challenges faced by the industry or the length of time to bring a product to market as key obstacles – these are reasonable challenges, but hurdles the pharma industry has managed to overcome.
 
As with all industries, the success factor is having the right people with the right skill sets to drive the innovation. There is also need for buy-in and commitment from senior management teams to support innovation within a the company. 
 
To be truly innovative, companies need people that have gone through the risk-taking experience, understand the processes involved and are willing to shield their innovation team when management starts looking for shorter-term gains.
 
By becoming more open and agile to innovating new ideas, adopting new technologies, business models and by focusing on customer requirements, the chemical industry still has a good chance of weathering this storm. 
 
Anil Vaidya has over 25 years of expertise the life science and healthcare sectors, focused on the areas of commercial and technical due diligence. 

Green Recovery Investments 267 views

Written by Michelle Lynch for CCD Partners
 

Evidence is mounting that a “green recovery” will be key to getting the economy back on track in the aftermath of the COVID-19 pandemic, focused on investment in the production of sustainable chemicals, materials, energy carriers and power systems.

 
There is a growing consensus that the “green recovery” will be key to getting the economy back on track in the aftermath of the COVID-19 pandemic. Researchers from Oxford University, UK recently published a study which pointed to green projects outperforming less sustainable options such as airline industry bailouts. 
 
Subsequently in conjunction with the International Monetary Fund (IMF), the International Energy Agency published its Sustainable Recovery Plan covering the period 2021-2023. 
 
The plan sets out three key aims: boosting economic growth, creating jobs, and building more resilient and cleaner energy systems. According to these reports, “building back better” will require investment in the production of sustainable chemicals, materials, energy carriers and power systems. 
 
Within those categories two areas will be considered in more detail here: i) hydrogen and ii) carbon dioxide capture, utilisation and storage (CCUS). Together these are attracting billions of dollars in investment. 
 
The territory is complex to navigate as there are many new innovative concepts for each, and a detailed understanding is required of the technologies and markets to make sound investment decisions. Some of the issues that need consideration are outlined below. 
 
1. Hydrogen. 
 
The majority of hydrogen is used as a feedstock to make chemicals and in the production of transportation fuels and other petroleum refinery products. More recently it has been employed for hydrogen fuel cells and this technology has moved from being a limited method of stationary source power to being a more mainstream transportation fuel in buses and trucks, mainly in China. Hydrogen fuel cells are now also in a small but growing number of passenger cars e.g. the Toyota Mirai and the company wants to make at least 1 million units by 2030. Hydrogen has been made for decades using processes known as “gasification” and “steam reforming” using coal and natural gas feedstocks. 
 
The production of hydrogen results in carbon dioxide (CO2) emissions. Currently 99% of hydrogen is made in this way and only 1% from a green method – water electrolysis. However, there is a strong and growing desire to decarbonise hydrogen production. In May this year, a group of electricity companies and industry associations including EDP, Enel, Iberdola, MHI Vestas, Orsted and SolarPower Europe launched a campaign called “choose renewable hydrogen” pushing the European Union to make renewable hydrogen a priority in its pandemic recovery plan. 
 
The options going forward to decarbonise hydrogen production include: use of a biobased feedstock e.g. biomass or biogas – Hazer Group in Australia is moving forward on this technology. Newer more efficient reforming methods such as autothermal reformers (ATR) and gas heated reformers (GHR) are in development, for instance at UK-based Johnson Matthey and partners. has These techniques would need to be combined with CCUS to be carbon neutral. There are also methods wihich avoid the generation of CO2 in the first place such as water electrolysis or methane pyrolysis. ITM Power, UK, Hydrogenics in Canada and a few others have water electrolysis technologies. Conversion of methane via a route which yields CO2-free hydrogen is seen as a “holy-grail” chemistry and many companies and research groups are working on such methods. Methane pyrolysis, for instance, takes natural gas and splits it into hydrogen gas and a useful solid carbon product such as carbon nanotubes (CNT). Gazprom in Russia is developing a methane pyrolysis method along with another route called methane adiabatic conversion (MAC). It is also working on its own water electrolysis technology. IHI Japan and CNRS France, TNO in The Netherlands and a German consortium based on BASF, Linde, and ThyssenKrupp are working on similar concepts for CO2-free methane.
 
In choosing a technology to invest in – one needs to be able to navigate the technology roadmap – with novel efficient reformers and bio-based feedstocks likely making an impact in the shorter term and a mixture of reforming with CCUS, water electrolysis in the medium-term and methane splitting and adiabatic conversion in the longer term. 
 
There is the possibility that one of these earlier stage technologies could make a significant breakthrough and leapfrog other concepts. 
 
Having a portfolio of investments across the different technology types may be a wise choice. 
 
2. CCUS. 
 
A key method in development for decarbonising chemicals production is to collect the point source CO2 emissions and either use them as a feedstock in place of virgin fossil fuels or to bury them in huge underground caverns on land or at sea. The benefit of the utilisation “U” part of the CCUS equation is that it allows the capture process to be monetised. For this reason, much of the CO2 currently captured is used in enhanced oil recovery (EOR), but there are many other options too. There are already technologies for making building materials such as cement, concrete and aggregates by turning CO2 back into solid carbonates – e.g. Carbon8 in the UK, Solidia, USA. In addition, it can be turned into a range of plastics – Econic Technologies, UK has a process for making CO2 into a feedstock for polyurethanes for instance and Newlight Technologies, USA ferments CO2 to make biodegradable polymers. 
 
Fuels are a key area of interest for CCUS – with many companies including Carbon Recycling International in Iceland (CRI) having a process to make CO2 into methanol for fuel. Breathe Industries in India also has such a process. Methane is another key target for CCUS and utilises “Power-To-Gas” technology by combining waste CO2 with electrolyser hydrogen in a process called “methanation”. Sunfire GmbH in Germany making significant headway with its version of this process. Specialty chemicals are another possibility. US-based Lanzatech takes off-gases from industrial plants such as steel factories and breweries and ferments them to make specialty alcohols as well as aviation fuels using its CarbonSmart™ platform. A start-up in Iceland – Gefn-ehf uses a set of reactors that look much like rubik’s cubes to pipe in a range of waste products from the oil and fat industry along with waste CO2 to make renewable chemicals such as glycerol carbonate for industrial solvents, household and personal care products. 
 
A key new technology for CCUS aims to remove CO2 from the air to bring the level back down to safe levels below 350 ppm. Climeworks in Switzerland, Carbon Engineering in Canada and Global Thermostat in the USA all have “direct air capture” (DAC) processes. DAC is currently much more expensive than CCUS and many researchers are looking to improve the DAC sorbent, which sits at the heart of the process. ExxonMobil is partnering with US-based materials manufacturer Mosaic Materials to come up with a metal organic framework (MOF) sorbent to improve the DAC process. Monetising DAC via CCUS is an important strategy and partnerships are being formed e.g. between Climeworks and Sunfire to make renewable methane. 
 
The CCUS sector is an ideal territory for investors and likely to become even more so over the next decade. Success of CCUS is based around partnerships along the supply chain from the emitter to the end-use application manufacturer. Investors can be guided in part by the presence of oil and gas majors, and large industrial majors within a start-up’s consortium, although it may be worth investing earlier for the most promising technologies. 
 
Dr Michelle Lynch offers consulting projects exclusively aimed at reducing the ecological footprint of chemicals, fuels, energy and power systems across their full lifecycles. 
 
She offers support to start-ups, SME’s, investors, multinational companies, government funding arms, and universities. Michelle runs her business out of London, UK and is passionate about helping technology developers to realise the goal of NetZero via high impact sustainable technology solutions. 

PE Explained 221 views

Written by CCD Partners
 

PE Explained: How it works, when to use it, and the 3 crucial calculations to understand

As the owner of a private company, you have likely considered ways to accelerate the growth and increase the value of your business. 
 
You may have explored fundraising routes to scale up output, strategic partnerships to widen distribution, or looked at ways to diversify and differentiate your commercial offering.  
 
The possibility of a majority investment from private equity (PE) may also feature among your options, but – like many business owners – you may have questions around the details of how such a partnership would work in practice.
 
CCD Partners meets regularly with private company owners who are curious to evaluate how a collaboration with PE could impact their business, as well as seeking to better understand the financial mechanics of such an investment. 
 
Typical questions include:
  • How does the PE model work?
  • What value does PE provide, beyond just cash?
  • What results / return are they targeting, and do I benefit?
  • How can I get the best deal?
This article is a walk-through of the basics of PE – designed to give private owners an idea of the types of questions they should be asking as they explore the option of working with PE. 
 
 
How PE works and when to use it
 
The underlying model of PE is relatively straightforward. They aim to buy low and sell high to realise gains for their own investors and themselves, typically over a 5-10 year time horizon.
 
Target returns and sample deal structure:
 
Although it can vary substantially, PE houses typically target a 3-10x overall return on their investments – equivalent to 20-40% per annum (compared to ~10% average stock market returns).
 
A typical deal might look like this:
  • A PE house values a company at £20m and acquires 75% from the owner for £15m. 
  • The PE house invests capital and provides expertise to help management significantly increase the value of the company, eventually selling for £120m. 
  • The original owner’s remaining 25% therefore nets them £30m – in addition to the £15m they had already banked on the initial transaction.
  • The PE firm has invested £15m (plus any investment capital), and sold for £90m, i.e. they have achieved an overall return of up to 6x.
As can be inferred from this example, the PE model is most effective for companies with significant value-creation potential that can be unlocked with an injection of capital and expertise. i.e. if your company could change from a £20m business to a £100m+ business in 4-5 years, and all this takes is capital and expertise, it could very well be an excellent option to consider. 
 
For private owners, what matters most (economically at least) in such a scenario is:
  • how much the PE house pays on entry (e.g. the £15m plus 25% equity), and 
  • how much might be achieved for the business on exit (e.g. the £120m).
 
The 3 crucial PE calculations
 
Once invested, the PE house will normally do a pretty good job maximising the chances of a high valuation on exit. 
 
The most important thing for private owners considering the PE route is to secure a good deal on entry.
 
Success here typically means: 
 
a) securing a high level of cash out, and 
b) retaining a healthy % of the equity.
 
How much any given PE house will pay you in cash and equity on entry is typically determined by the “3 crucial calculations” mentioned in the title. 
 
Understanding these 3 calculations is vital for private owners preparing to enter discussions with PE. 
 
This is a broad topic, but we have attempted to distill it down to PE’s top 3 considerations under each heading, as follows:
 
1. Exit Valuation – What is the expected value in 5 years’ time?
  • Market trend / customer pull – What is the current and projected future demand for the company’s product or service?
  • Competitive advantage – Do clients want the company’s specific service or product over other options? 
  • Exit options – How easily will the PE house be able to sell the company at the end of their investment lifecycle?
2. Journey Risk – How risky they think it will be (and how long) to get from entry to exit?
  • Organic factors – Does the journey require organic growth? How will that be achieved? What does it require? How risky is it? 
  • Inorganic factors – Does the journey require bolt-on or other acquisitions? How will that be achieved? What does it require? How risky is it?
  • Leadership – The PE house will need to believe in and trust the management team, whether that includes existing management or new recruits.
3. Entry Price – How much they have to pay to persuade you to sell to them? (Crucially, this is not the same as their valuation of the company).
  • Presented value – Does the PE house think you know the full transformative potential of your business – For instance, if you forecast your business to reach £100m in value but they think £400m is possible, would they tell you?
  • Data quality – Can they find any errors, risks, or concerns in your business plan (or your presentation of it) – If you agree a price of £20m but then a number of holes in your plan are discovered, even if these are not big value points, how much will they reduce the £20m? 
  • Other options – Do they think you have any other options – If they reduce their price by 20% would you still accept it? 
 
Optimal strategy – How to get the most out of PE 
 
Matched with the right company on the right terms, PE can unlock significant value. 
 
For private owners to fully participate in this value-creation requires an understanding of how PE houses approach investment opportunities and their rationale for both selecting and pricing investments.
 
Though by no means exhaustive, the below serves as a starting point for private owners looking to develop their own PE engagement strategy. 
 
1. Develop a PE-focused business plan, supported by:
    1. Market trend / customer pull data and rationale
    2. Competitive advantage data and rationale
    3. Exit options data and rationale
    4. Details of organic growth required
    5. Details of any corporate acquisitions required (if any)
 
A business plan specifically tailored to PE which demonstrates a detailed playbook for PE-backed value creation differs significantly from typical standalone corporate business plans. 
 
2. Have a top-notch leadership team in place, or at least available, preferably with:
    1. Prior (successful) experience with PE and M&A
    2. An amount of time in the business or engaged with the business
    3. All roles required for the business plan filled, or with detailed plans in place
 
Forward planning for the personnel involved in bringing the PE-backed growth plan to life is essential. Many PE houses do not like incomplete management teams, presenting a full management solution greatly widens the field of potential investors, which in turn greatly increases the potential pricing of any deal that might be secured.
 
3. Do your own due diligence:
    1. Collate and review all the documents PE would review in their due diligence process
    2. Build your business plan up from primary data that can be analysed and cut in multiple ways
    3. Make sure any “skeletons” are dealt with up front before pricing is agreed
 
Vendor due diligence not only protects business owners from surprises (and subsequent price negotiations) but also facilitates building an extremely credible thought-through business plan that investors can believe in. 
 
4. Run a professional process:
    1. Convince the PE firm that you know what you’re doing
    2. Use professional negotiators
    3. Use competitive tension
 
In any sale process format (from one-on-one to wide auctions), sellers are vulnerable to significant price reductions during late stages of due diligence and final pricing. The primary defences against this are 1) showing you can walk away to other options, 2) pointing to pre-agreed pricing mechanics and market norms, and 3) the threat of reputational damage (in the competitive world of PE it is advantageous to maintain a good reputation amongst the advisory community).
 
 
In short, if they want to avoid leaving significant value on the table, private owners should ensure they approach and engage PE with a well-defined strategy – one that protects their short and long-term interests and works to lay the foundations for a win-win partnership.
 
***
 
If you are a private company owner interested in the potential of private equity to unlock the transformative potential of your business, please contact CCD Partners for a confidential discussion. 
 
CCD Partners manages a network of regional, international, and sector-specialist investors in the chemicals and life sciences sectors, and works with business leaders planning for and securing investments that unlock the next chapter of their company’s growth.

ESG – An investment touchstone made real by Covid-19? 128 views

Written by Roger Green for CCD Partners

Could a renewed focus on Environmental, Social and Governance (ESG) be the start of a ‘green recovery’?

Ethics and economics have not always moved in lockstep in the world of business investment. 
 
This is set to change for good in the chemical industry with a renewed focus upon environmental social and governance (ESG) factors. There are two principal drivers of rapid change in the chemical industry, the first comes from a perhaps unlikely source: the Covid 19 pandemic. Whilst causing economic damage the crisis has unleashed a wave of government fiscal support and this concerted government action brings a greater ESG oversight than might be the case otherwise, with governments focusing on a green recovery (1) post Covid. A second, industry specific driver of change derives from a perceived weak performance, specifically in terms of carbon intensity and plastics waste, which pose an existential threat to sectors of the industry and make change an imperative. 
 
Ethical and ESG investments have outperformed the wider market in recent years(2), a trend that is both heartening to see and expected to continue. Indeed, if further evidence were needed, it appears that the converse applies. Taking the tobacco industry as an example of a sector which would fail most ethical screening tests, stable, often robust financial performance over the past three years, including great resilience during the pandemic, has been ‘rewarded’ with a near halving of enterprise value for a number of the majors.
 
Turning to the chemical sector, we see change afoot. Global majors are not always the most agile of corporations, however we should certainly take note of the announcements by Unilever and BP. Oil major BP set out an ambition of ‘net zero by 2050’ and consumer goods leader Unilever has pledged to replace all fossil carbon in its cleaning and laundry product formulations with renewable or recycled carbon by 2030. It is likely that these announcements will be looked back upon as the point of inflection at which the industry dynamic changed for all time.
 
As consumer sentiment swings relentlessly towards increased awareness of environmental performance, major corporations are enshrining these principles in their business objectives. It is therefore essential that chemical industry players and investors alike align business models with the changes that are set to sweep through the sector.
We can identify three key axes which are going to play a prominent role in the transformation of the sector, namely decarbonisation, biotransformation, and circularity. The themes are not exclusive; indeed, they are neatly circular themselves with biotransformation of (circular) waste leading to decarbonisation, for example.
 
At CCD Partners we have seen and increasing appetite for transactions built on sustainable technologies and some really exciting technologies built on biotransformation and decarbonisation.
 
Whilst there are no certainties in investment, catching the Zeitgeist of outstanding ESG credentials whilst swimming with the ‘green recovery’ tide provides a very sound foundation for success in the post-Covid era.
 
(2) Majority of ESG funds outperform wider market over 10 years. Siobhan Riding, Financial Times, June 13 2020.

The IM – An SME Seller’s Guide 137 views

Written by Matt Dixon for CCD Partners 
 
The creation of an Information Memorandum (IM) when selling a business can often be considered something of a formality – a pragmatic stepping-stone designed to introduce an opportunity and open dialogue with prospective buyers. 
 
In fact, the IM is a strategic document of vital importance – one that can have enduring impact on the pace, structure, and outcome of negotiations, anchoring the process and directly affecting the eventual sale price.
 
Based on decades of working with lower mid-market chemicals and life sciences businesses to achieve exits at market-beating valuations (often by more than 40%), and reviewing hundreds of IMs of varying quality on behalf of buyers and investors, the CCD Partners team shares its thoughts on creating successful sell-side materials:
 
Why IMs often fall short in the SME market 
 
Unlike bigger businesses where detailed vendor due diligence is common practice and teams of external advisers prepare highly detailed and relatively standard-format IMs, smaller businesses’ sale materials and, in particular, those prepared by DIY-sellers, are far more variable, often erring on the side of “less is more” and focusing on their own products and services rather than the value of the business as a whole to the potential buyer. At the same time smaller companies are often far less well understood than larger higher-profile companies – so, if anything, they need more, broader information in their IMs, not less.
 
The frustrating thing for us as advisors is that we see a lot of such DIY-seller IMs and we know the DIY-seller is unlikely to ever find out their IM has seriously undermined their position.  
 
Many buyers, who are often juggling multiple opportunities (often larger than the seller’s), will simply judge the IM on the basis of a cursory read and simply signal “no interest” without telling the seller that the IM failed to make clear why the buyer should be interested. 
 
Furthermore, such a DIY IM tells an interested, experienced buyer that the seller is inexperienced, so the buyer is emboldened to make unusually buyer-friendly demands or simply offer a lower price than they would be ultimately prepared to pay.
 
Getting it right 
 
An effective IM, therefore, addresses both of these problems: 
 
Initially, it catches buyers’ attention above other opportunities on their desks by clearly signalling that further assessment of this opportunity has a good chance of being worth their while – by both setting out the value of the opportunity to the buyer (high value), and making it obvious that information and data is readily available for review (low cost). 
 
Secondly, a well-produced IM will demonstrate to investors that the seller has experience negotiating M&A deals (or has such experience in their corner) and is well prepared. It will use the right wording and nomenclature, it will set out and define the key financial metrics common to most M&A deals, it will include references to further backing information and diligence reports, it will start building a clear platform for later negotiations (for example, listing areas of potential synergy with buyers), and will make all the necessary disclosures and address any areas of potential weakness up front.  
 
IMs which achieve these goals are usually simple in structure, built around a central narrative that dives progressively deeper into the same core pitch, walking the buyer through the opportunity and offering more and more granular levels of supporting data to continually reinforce the narrative. 
 
Building the narrative 
 
Although every IM is unique, we recommend that every seller should seriously consider the following workstreams to develop the fundamental building blocks of a pack of transaction-focused sales materials: 
  • Market review and competitive landscape 
  • Business plan (with and without external investment scenarios) 
  • Historic and forecast P&L, BS, and Cash Flow (preferably monthly) 
  • Working capital and capex analyses 
  • Quality of earnings analysis 
  • IP/Patent analysis where applicable
  • Identification of synergies that may be available to buyers 
These building blocks are then used to inform and underpin the IM which should tie together between five and eight key stand-out facts about the business (often referred to as “investment highlights”) into one cohesive and consistent transaction narrative that can be repeated across all core sales materials (pitch, teaser, IM, management presentations, full data suite). 
 
The first step in capturing value 
 
Contrary to many business owners’ natural instincts, an IM should be a more nuanced and complex tool than a straightforward ‘profile’ of their company. 
Well-executed IMs serve to: 
  • engage the best-matched buyers effectively 
  • present a clearly-structured value opportunity 
  • demonstrate seller sophistication
  • lock-in terms favourable to the seller from the outset 
IMs represent a highly strategic step in capturing maximum shareholder value and can materially impact the eventual sale price and deal structure secured from potential buyers. 
 
This is well understood at larger scales, but often seems to get lost in the lower-mid market. Even for businesses selling for as little as £5m, relatively modest swings in value (or a swing from no sale at all) can easily surpass the cost associated with building a top-quality IM. 
 
In our experience, top-quality professional IMs are well worth the investment.

Welcome to Chloe, NobleNet’s new digital media specialist 169 views

Delighted to welcome Chloe Neil to the team at Chemical Search International. Chloe joins to spearhead development of our digital marketing channels, both for Chemical Search and our new sister venture www.staging.noblenet.co, launching fully next month. Chloe is based in our London office and has a degree in Fine Arts from the University of Brighton and a passion for harnessing the power of digital media for business growth. NobleNet members will be hearing a lot more from her.

Welcome Chloe!

NobleNet 313 views

Welcome to NobleNet 

Thanks for joining us! Its always hard launching a new venture, especially in the current uncertain world, so we hope that you like the site and that we can help you in some way. 

If you can read this it means you have completed the essential fields on your record but please spend a little time when you can enriching your profile – you can paste your CV/Resume into the freeform field called Detailed Profile if you like which is fully searchable and a quick way of sharing your experience.

Please share any thoughts or views you may have on the site or start discussions of your own on this Discussions area.

Thanks again and if you like our site, please tell others.

All the best, Stephen